Fig. 1 · Structure

Documents & Downloads

Palovarotene

Cat. No. A12430 CAS 410528-02-8
Palovarotene is a novel retinoic acid receptor gamma agonist for the treatment of emphysema

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Palovarotene Research Summary

This section summarizes 2 in vitro studies and 2 in vivo studies of Palovarotene from 3 published references.

Palovarotene In Vitro Studies

In growth plate chondrocytes isolated from ribs and sterna, 50 nM Palovarotene significantly decreased extracellular matrix Alcian blue staining compared with vehicle control cultures. In AcanCreER;Ext1f/f chondrocytes treated with 300 nM Palovarotene for 2 days, bulk RNA-seq comparison with control chondrocytes identified 2582 genes significantly upregulated and 2222 genes downregulated. [1,2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Palovarotene decreases extracellular matrix Alcian blue staining

Cell-based study · growth plate chondrocytes were isolated from P3 ribs and sterna [1]

Growth plate chondrocytes isolated from ribs and sterna were treated with 50 nM Palovarotene added to the culture medium. Alcian blue staining of the extracellular matrix decreased significantly compared with vehicle control cultures.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Alcian blue staining of the extracellular matrixReported result Day 4 and day 7; palovarotene (50 nM): significant drop in Alcian blue staining of the extracellular matrix compared with vehicle control cultures.[1]

Literature-Reported Treatment Conditions

Treatment concentration
50 nM
Exposure duration
Starting on day 1; Fresh medium and drug were given every other day; Cultures were harvested on days 4 and 7
Method
added to the culture medium
Co-treatment
Other interventions in this design: beta‐glycerophosphate; ascorbic acid. Compound effect isolated by the comparison: compared with vehicle control cultures.
Reported limits
Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Palovarotene

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and Methods > Preparation, treatment, and analysis of growth plate chondrocyte cultures (S66, S67); Results > Palovarotene does not reduce Inhba expression in chondrogenic cells in vitro (S148, S149, S150); Fig. 8 legend (S194)

Alcian blue staining of the extracellular matrix: Alcian blue staining of the extracellular matrix; comparator: vehicle control cultures — Results > Palovarotene does not reduce Inhba expression in chondrogenic cells in vitro (S150); Fig. 8 legend (S194)

Palovarotene alters chondrocyte gene expression

Cell-based study · AcanCreER;Ext1f/f chondrocytes [2]

AcanCreER;Ext1f/f chondrocytes were treated with 300 nM Palovarotene or vehicle ethanol for 2 days. Bulk RNA-seq comparison of Palovarotene-treated and control chondrocytes identified 2582 genes significantly upregulated and 2222 genes downregulated.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
bulk RNA-seqdifferentially expressed genes AcanCreER;Ext1f/f chondrocytes; 300 nM palovarotene for 2 days: 2582 genes significantly upregulated and 2222 genes downregulated[2]

Literature-Reported Treatment Conditions

Treatment concentration
300 nM
Exposure duration
acclimated to culture for 2 days, and treated with 300 nM palovarotene or vehicle ethanol for 2 days
Vehicle
ethanol
Co-treatment
Other interventions in this design: tamoxifen 40 mg/kg. Compound effect isolated by the comparison: palovarotene-treated and control AcanCreER;Ext1f/f chondrocytes.
Reported limits
Not stated in the sentences used: route.
Methods and source locations

Compound reported in the paper: Palovarotene

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

2. Results > 2.4. Actions of Palovarotene on Cultured Chondrocytes (S46, S47, S48, S50); 4. Materials and Methods > 4.1. Animals (S81)

bulk RNA-seq: bulk RNA-seq; comparator: vehicle ethanol — 2. Results > 2.4. Actions of Palovarotene on Cultured Chondrocytes (S47, S48, S50)

Palovarotene In Vivo Studies

Daily intraperitoneal Palovarotene treatment reduced total body HO/overgrowth burden by ~50% in Acvr1tnR206H/+;R26NG/+;Pdgfrα-Cre mice. Daily treatment at 0.735 mg/kg or 1.47 mg/kg did not improve survival compared with vehicle-treated mice. [3]

Palovarotene reduces total body HO and overgrowth burden

Animal study · Acvr1tnR206H/+;R26NG/+;Pdgfrα-Cre mice [3]

Acvr1tnR206H/+;R26NG/+;Pdgfrα-Cre mice received daily intraperitoneal injections of Palovarotene at 0.735 mg/kg or 1.47 mg/kg. Treatment reduced total body HO/overgrowth burden by ~50%.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Total body HO/overgrowth burdenTotal body HO/overgrowth burden 0.735 mg/kg palovarotene, 1.47 mg/kg palovarotene; daily administration from P14 through P41; P42: reduced ~50%[3]

Conditions shared by the study groups

Route
intraperitoneal (IP) injections
Treatment course
daily administration
Vehicle
0.735% DMSO with 4% Tween 80 in PBS (pH 7.4); 0.147 mg/mL palovarotene in 1.47% DMSO with 4% Tween 80 in PBS (pH 7.4)
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Palovarotene 0.735 mg/kg palovarotene, 1.47 mg/kg palovarotenevehicle-treated Pdgfrα-R206H miceTotal body HO/overgrowth burden was reduced ~50% by palovarotene treatment[3]
Palovarotene 0.735 mg/kg palovarotene, 1.47 mg/kg palovarotene
Model: Acvr1tnR206H/+;R26NG/+;Pdgfrα-Cre mice
Methods and source locations

Compound reported in the paper: Palovarotene

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > Daily palovarotene treatment ameliorates HO and osteochondroma formation in juvenile Pdgfrα-R206H mice (S23, S33, S34); Materials and methods > Reagents (S101); Materials and methods > Daily palovarotene dosing (S105); Figure 2. legend (S181)

Total body HO/overgrowth burden: Total body HO/overgrowth burden; comparator: vehicle-treated Pdgfrα-R206H mice — Results > Daily palovarotene treatment ameliorates HO and osteochondroma formation in juvenile Pdgfrα-R206H mice (S23, S34); Figure 2. legend (S181)

Palovarotene 0.735 mg/kg palovarotene, 1.47 mg/kg palovarotene · Results > Daily palovarotene treatment ameliorates HO and osteochondroma formation in juvenile Pdgfrα-R206H mice (S23, S34); Materials and methods > Daily palovarotene dosing (S105)

Survival Outcomes Following Treatment in Mice

Animal study · Acvr1tnR206H/+;R26NG/+;Pdgfrα-Cre mice [3]

Acvr1tnR206H/+;R26NG/+;Pdgfrα-Cre mice received daily intraperitoneal Palovarotene or vehicle. Palovarotene did not improve survival compared with vehicle-treated mice.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
P42 survival ratesurvival P42 survival rate of 27% for 0.735 mg/kg palovarotene-treated mice and 33% for 1.47 mg/kg palovarotene-treated mice[3]

Conditions shared by the study groups

Route
intraperitoneal (IP) injections
Treatment course
daily administration of 0.735 mg/kg palovarotene, 1.47 mg/kg palovarotene, or vehicle alone from P14 through P41
Vehicle
0.735% DMSO with 4% Tween 80 in PBS (pH 7.4); 0.147 mg/mL palovarotene in 1.47% DMSO with 4% Tween 80 in PBS (pH 7.4)
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Palovarotene 0.735 mg/kg palovarotene, 1.47 mg/kg palovarotene47% of vehicle-treated Pdgfrα-R206H mice survived to P42palovarotene did not improve survival of Pdgfrα-R206H mice, with a P42 survival rate of 27% for 0.735 mg/kg palovarotene-treated mice and 33% for 1.47 mg/kg palovarotene-treated mice[3]
Palovarotene 0.735 mg/kg palovarotene, 1.47 mg/kg palovarotene
Model: Acvr1tnR206H/+;R26NG/+;Pdgfrα-Cre mice
Methods and source locations

Compound reported in the paper: Palovarotene

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > Daily palovarotene treatment ameliorates HO and osteochondroma formation in juvenile Pdgfrα-R206H mice (S23, S25, S26); Materials and methods > Reagents (S101); Materials and methods > Daily palovarotene dosing (S105); Figure 2. legend (S179)

P42 survival rate: P42 survival rate; comparator: 47% of vehicle-treated Pdgfrα-R206H mice survived to P42 — Results > Daily palovarotene treatment ameliorates HO and osteochondroma formation in juvenile Pdgfrα-R206H mice (S26)

Palovarotene 0.735 mg/kg palovarotene, 1.47 mg/kg palovarotene · Results > Daily palovarotene treatment ameliorates HO and osteochondroma formation in juvenile Pdgfrα-R206H mice (S23, S26); Materials and methods > Daily palovarotene dosing (S105)

Specifications

Manufacturer Adooq Bioscience
Actions Agonist
CAS Number 410528-02-8
Formula C27H30N2O2
Molecular Weight 414.54
SMILES
CC1(CCC(C2=C1C=C(C(=C2)/C=C/C3=CC=C(C=C3)C(=O)O)CN4C=CC=N4)(C)C)C

Storage & Solubility

In Vitro Solubility

Reported Solubility

No reported solubility data are available for this product.

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Palovarotene Research References

  1. [1] Mundy C, Yao L, Shaughnessy KA, et al. Palovarotene Action Against Heterotopic Ossification Includes a Reduction of Local Participating Activin A-Expressing Cell Populations. JBMR Plus (2023). PMID: 38130748 DOI: 10.1002/jbm4.10821 Source material
  2. [2] Garcia SA, Wilson K, Tang N, et al. Analysis of the Actions of RARγ Agonists on Growing Osteochondromas in a Mouse Model. Int J Mol Sci (2024). PMID: 39062860 DOI: 10.3390/ijms25147610 Source material
  3. [3] Lees-Shepard JB, Nicholas SE, Stoessel SJ, et al. Palovarotene reduces heterotopic ossification in juvenile FOP mice but exhibits pronounced skeletal toxicity. Elife (2018). PMID: 30226468 DOI: 10.7554/eLife.40814 Source material

Added to your cart

View Cart Checkout
Loading...